The White House physician allows the president to attend public events starting Saturday; study details long-term coronavirus disease 2019 symptoms in pregnant women; new poll shows record low approval of the pandemic response.
President Donald Trump’s White House physician Sean Conley said the president is able to make a safe return to public events on Saturday, less than 2 weeks after the president tested positive for coronavirus disease 2019 (COVID-19) late on October 1, The Hill reports. According to the CDC, individuals should only resume interactions with others 10 days after symptom onset. Conley said Saturday marks day 10 since the president’s diagnosis and that the president had completed his therapy for COVID-19. As Trump received treatment at Walter Reed National Military Medical Center for 2 days, some health experts question Conley’s assessment, noting some patients with severe COVID-19 symptoms may be infectious for longer than 10 days.
Although most pregnant women with COVID-19 experience a mild form of the disease, many exhibit prolonged symptoms lasting weeks after infection, CIDRAP reports. A new study published in Obstetrics & Gynecology followed nearly 600 pregnant women who tested positive for COVID-19 during pregnancy and reported symptoms at the time of testing. After 3 weeks, 48% of participants were still symptomatic, and symptoms persisted for 8 weeks or longer in 25% of the women. However, 60% of participants reported no symptoms after 4 weeks. Of the 594 women included in the study, 27 were hospitalized and 11 were admitted to intensive care units.
A recent Reuters/Ipsos poll, conducted after the president tested positive for COVID-19, showed just 37% of Americans approve of Trump’s handling of the pandemic, compared with 59% of respondents who disapproved. The net approval rating of –22 percentage points marks the lowest in the poll, which dates back to March 2. Over the last 10 days, approval ratings have steadily declined, coinciding with the president’s diagnosis and return to work in the White House. In comparison, Trump’s rating on pandemic response was –11 percentage points in a previous poll taken from September 30 through October 1.
Study Highlights BMP7 As a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More